PoA = probability-of-approval band (directional only; not FDA guidance).
Rule: FDA decision events get a %; data/KOL/conference events get N/A.
THE FRAME (MAR 6–MAR 11): “CMC PRINT → MDA WEEK (DATA SHAPE > HEADLINES)”
This is a clean handoff from one hard FDA clock into a compressed neuromuscular volatility window:
Today (Fri): $LNTH ( ▼ 4.91% ) prints a CMC/formulation PDUFA (supply + manufacturing language matters).
Next week (Mon–Wed): retina call $NBP , MASH KOL $GALT ( ▲ 2.31% ) , then back-to-back MDA late-breakers $BBIO ( ▼ 1.22% ) → $CAPR ( ▲ 8.06% )
Forward setup: March 16 becomes the next “double-event day” $ALDX ( ▲ 3.23% ) PDUFA + $RLAY ( ▲ 2.59% ) ESMO TAT.
TODAY’S HARD CLOCK
LNTH — $LNTH ( ▼ 4.91% ) | PYLARIFY (piflufolastat F-18) new formulation | PDUFA: Fri Mar 6 | PoA: 92
What this is: a CMC / manufacturing optimization submission (not a clinical efficacy bet), anchored on ~50% batch size increase + concentration optimization.
What will trade:
Bull language: “unrestricted supply / capacity expansion” tone and clean commercialization framing.
Bear surprise: any PMC / validation-batch requirement that delays realizing the capacity expansion.
Ops note: CMC supplement actions don’t always come with a classic FDA press release—watch company IR and Drugs@FDA for the first definitive “print.”
IMMEDIATE VISIBILITY / TRADEABLE WINDOWS (NEXT ~5 DAYS)
NBP — $NBP | VIS-101 (VEGF-A/ANG-2) | Phase 2a data call: Mon Mar 9, 9:00am ET | PoA: N/A
This trades durability + differentiation vs Eylea/Vabysmo expectations.
Tape-movers:
durability/interval framing (even if implied, not explicit)
safety tone (IO inflammation / discontinuations)
whether the “next trial shape” is crisp (Phase 2b/3 path language)
This is a narrative repair / positioning event: subgroup + biomarker + next-trial posture.
Tape-movers:
whether KOLs treat subgroup signal as actionable vs “interesting”
clear articulation of next endpoint + population (design clarity is the trade)
MDA WEEK (MAR 8–11): THE COMPRESSED WINDOW
BBIO — $BBIO ( ▼ 1.22% ) | BBP-418 (FORTIFY interim) | Late-breaking oral: Wed Mar 11, 2:00pm ET | PoA: N/A
High-vol setup because it runs back-to-back with $CAPR.
What will trade:
whether the interim analysis is clinically interpretable (not just “encouraging”)
the mechanistic coherence investors will latch onto: ribitol response / FKRP framing and what it implies for responders vs non-responders
CAPR — $CAPR ( ▲ 8.06% ) | deramiocel (HOPE-3) | Late-breaking oral: Wed Mar 11, 2:45pm ET | PoA: N/A
This week is the start of the catalyst window; the focal point is the late-breaking oral.
What will trade:
effect size on PUL / functional endpoints with cohort clarity
durability + how cleanly the cardiac angle ties back to meaningful function
“reg path” language (what FDA needs next, not what bulls want)
QUICK CALENDAR (MAR 6–MAR 16)
Day | Ticker | Event | Why it matters |
|---|---|---|---|
Fri Mar 6 | PDUFA (PYLARIFY new formulation) | clean CMC print; PMCs/conditions are the only real surprise vector | |
Mon Mar 9 (9:00am ET) | $NBP | Phase 2a data call | retina durability vs incumbents tape |
Tue Mar 10 (12:00pm ET) | Virtual KOL | subgroup/biomarker + next-trial design clarity | |
Wed Mar 11 (2:00pm ET) | MDA late-breaker | interim FORTIFY; interpretability + FKRP/ribitol lens | |
Wed Mar 11 (2:45pm ET) | MDA late-breaker | HOPE-3 readout; functional effect size + durability | |
Mon Mar 16 | PDUFA (reproxalap) | CRL-overhang name; label/efficacy posture is the trade | |
Mon Mar 16 | ESMO TAT | zovegalisib data at Phase 3 dose (400mg BID fed); watch safety profile vs PI3K baggage |
CLOSING NOTE
Trade the documented clock + the next explicit step:
Today: $LNTH prints (CMC posture; language/conditions matter).
Next week: MDA late-breakers are a dataset-shape market—durability, effect size, and cohort clarity decide the tape.
Tools we use: Market Chameleon (options/IV + unusual activity). We may earn a commission at no extra cost to you.
Disclaimer: informational only; not investment advice; biotech carries risk of total loss